| Gene symbol | F | Synonyms | None | Type of gene | protein-coding | |
| Chromosome | - | Map location | NC_001803.1 (5619..7521) | dbXrefs | Entrez:1494475 - | |
| Description | Fusion protein (F) | |||||
| GTO ID | GTC3633 |
| Trial ID | NCT06097299 |
| Disease | Respiratory Syncytial Virus Infectious Disease |
| Altered gene | F |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1345 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease |
| Year | 2023 |
| Country | United States|Panama |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1345-P202|2023-506271-96-00 |
| Vector information | |||
|
|||
| Cohort1: Participants 2 to <5 years | |||||||
|
|||||||
| Cohort2: Participants 5 to <18 years | |||||||
|
|||||||